I. Arnott

H. Drummond, I. Arnott, S. Ghosh, 2002, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Detailed assessment of NOD2/CARD15 exonic variation in inflammatory bowel disease in Scotland: implications for disease pathogenesis

H. Drummond, E. Nimmo, J. Satsangi, 2008, Genes and Immunity.

The organisation and structure of inflammatory bowel disease services for children and young people in the UK in 2010: significant progress but still room for improvement

R. Russell, M. Roughton, I. Arnott, 2012, Frontline Gastroenterology.

Systemic inflammation in pre-clinical ulcerative colitis.

S. Heath, H. Drummond, C. Lees, 2021, Gastroenterology.

The requirements and barriers to successful transition of adolescents with inflammatory bowel disease: differing perceptions from a survey of adult and paediatric gastroenterologists.

R. Russell, S. McCartney, S. Sebastian, 2012, Journal of Crohn's & colitis.

Magnetic resonance follow‐through imaging for evaluation of disease activity in ileal Crohn's disease: An observational, retrospective cohort study

J. Satsangi, C. Mowat, C. Parisinos, 2010, Inflammatory bowel diseases.

Efficacy and complications of adalimumab treatment for medically‐refractory Crohn’s disease: analysis of nationwide experience in Scotland (2004–2008)

C. Lees, J. Satsangi, C. Mowat, 2009, Alimentary pharmacology & therapeutics.

The safety profile of anti‐tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient‐years follow‐up

C. Lees, J. Satsangi, R. Forsythe, 2009, Alimentary pharmacology & therapeutics.

Gut luminal neutrophil migration is influenced by the anatomical site of Crohn's disease

H. Drummond, I. Arnott, S. Ghosh, 2001, European journal of gastroenterology & hepatology.

IBD prevalence in Lothian, Scotland, derived by capture–recapture methodology

C. Lees, P. Henderson, I. Arnott, 2019, Gut.

Patient involvement in IBD Service Standards and Quality Improvement.

I. Arnott, A. Hawthorne, Rukshana Kapasi, 2020, Journal of Crohn's & colitis.

Multiple liver lesions in a smoker

I. Arnott, K. Palmer, S. Glancy, 2007, Gut.

The use of adalimumab in the management of refractory Crohn’s disease

C. Lees, J. Satsangi, I. Arnott, 2007, Alimentary pharmacology & therapeutics.

Quality of care standards in inflammatory bowel diseases: a European Crohn's and Colitis Organisation (ECCO) position paper.

J. Gisbert, A. Hart, G. Fiorino, 2020, Journal of Crohn's & colitis.

Contemporary Outcomes for Ulcerative Colitis Inpatients Admitted to Pediatric Hospitals in the United Kingdom

R. Russell, M. Roughton, I. Arnott, 2013, Inflammatory bowel diseases.

Prognostic factors associated with unhealed perineal wounds post‐proctectomy for perianal Crohn's disease: a two‐centre study

A. Hart, I. Arnott, J. Warusavitarne, 2021, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

efinition of Phenotypic Characteristics of Childhood-Onset Inflammatory owel Disease

H. Drummond, E. Nimmo, J. Satsangi, 2008 .

Edinburgh Explorer Definition of Phenotypic Characteristics of Childhood-Onset Inflammatory Bowel Disease

H. Drummond, E. Nimmo, J. Satsangi, 2008 .

Gut Mucosal Secretion of Interleukin 1β and Interleukin-8 Predicts Relapse in Clinically Inactive Crohn's Disease

H. Drummond, Subrata Ghosh, I. Arnott, 2001, Digestive Diseases and Sciences.

Inflammatory bowel disease patient‐reported quality assessment should drive service improvement: a national survey of UK IBD units and patients

A. Nevill, C. Lamb, R. Muhammed, 2022, Alimentary pharmacology & therapeutics.

Analysis of colectomy rates for ulcerative colitis in pre‐ and postbiological eras in Lothian, Scotland

C. Lees, I. Arnott, K. Kirkwood, 2020, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

Temporal Trends in Surgical Resection Rates and Biologic Prescribing in Crohn's Disease: A Population-based Cohort Study.

C. Lees, I. Arnott, S. Siakavellas, 2020, Journal of Crohn's & colitis.

Implementation of CT-P13 via a Managed Switch Programme in Crohn’s Disease: 12-Month Real-World Outcomes

C. Lees, I. Arnott, G. Ho, 2018, Digestive Diseases and Sciences.

Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysis

C. Lees, R. Russell, P. Henderson, 2022, Alimentary pharmacology & therapeutics.

Inflammatory bowel disease clinical service recovery during the COVID-19 pandemic

C. Lamb, G. Moran, D. Gaya, 2021, Frontline Gastroenterology.

P483 Impact of inflammatory bowel disease nurse specialist on quality of the patient journey

I. Arnott, E. Fernandez, K. Kemp, 2013 .

The spectrum of ischaemic colitis.

A. Ferguson, I. Arnott, S. Ghosh, 1999, European journal of gastroenterology & hepatology.

Role of infliximab in ulcerative colitis: further questions.

C. Lees, J. Satsangi, I. Arnott, 2006, Inflammatory bowel diseases.

Higher anti-tumor necrosis factor levels are associated with perianal fistula healing and fistula closure in Crohn's disease.

C. Lees, I. Arnott, N. Plevris, 2019, European journal of gastroenterology & hepatology.

Use of methotrexate in refractory Crohn's disease: The Edinburgh experience

J. Satsangi, I. Arnott, A. Shand, 2008, Inflammatory bowel diseases.

OC-165 No increase in surgical complication in patients treated with rescue therapy for acute severe ulcerative colitis: data from the UK IBD audit

M. Roughton, I. Arnott, C. Down, 2012, Gut.

763 Outcome of Acute Severe Ulcerative Colitis: Data From the UK National IBD Audit

J. Potter, J. Rhodes, D. Lowe, 2010 .

Capsule endoscopy in suspected small bowel Crohn's disease - Is it worth repeating a negative study?

Anastasios Koulaouzidis, I. Arnott, J. Plevris, 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Recommendations for the optimal use of mesalazine in the management of patients with mild to moderate ulcerative colitis

N. Kennedy, A. Fraser, I. Arnott, 2022, Gastrointestinal Nursing.

Recommendations for the optimal use of mesalazine in the management of patients with mild to moderate ulcerative colitis.

N. Kennedy, A. Fraser, I. Arnott, 2021, British journal of hospital medicine.

What is the risk that a child will develop inflammatory bowel disease if 1 or both parents have IBD?

I. Arnott, C. Noble, 2008, Inflammatory bowel diseases.

P318 The prevalence of anaemia in inflammatory bowel disease in relation to disease activity, as stratified by faecal calprotectin

C. Lees, J. Satsangi, N. Kennedy, 2013 .

Crohn’s disease or Crohn’s diseases?

J. Satsangi, I. Arnott, 2003, Gut.

Profound diarrhoea and weight loss in an immunocompromised patient

I. Arnott, A. Shand, S. Din, 2021, BMJ Case Reports.

P263 Definition of phenotypic characteristics of late onset IBD

C. Lees, J. Satsangi, M. Porteous, 2013 .

The Value of a Dedicated IBD Flare Clinic to Effectively Manage Exacerbations of Inflammatory Bowel Disease: The Edinburgh IBD Unit.

I. Arnott, R. Grant, William M Brindle, 2022, Inflammatory bowel diseases.

Toll-like receptor 4 gene in IBD: further evidence for genetic heterogeneity in Europe.

J. Satsangi, E. Nimmo, I. Arnott, 2005, Gut.

Guidelines for the management of inflammatory bowel disease in adults

C. Lees, J. Satsangi, C. Mowat, 2011, Gut.

Genetics of the innate immune response in inflammatory bowel disease.

E. Nimmo, J. Satsangi, R. Russell, 2007, Inflammatory bowel diseases.

Genetic Variation in the Familial Mediterranean Fever Gene (MEFV) and Risk for Crohn's Disease and Ulcerative Colitis

T. Hudson, J. Rioux, E. Nimmo, 2009, PloS one.

Investigation of NOD1/CARD4 variation in inflammatory bowel disease using a haplotype-tagging strategy.

H. Drummond, E. Nimmo, J. Satsangi, 2007, Human molecular genetics.

Fecal Calprotectin Predicts the Clinical Course of Acute Severe Ulcerative Colitis

H. Drummond, J. Satsangi, M. Dunlop, 2009, The American Journal of Gastroenterology.

Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease.

David C Wilson, Jack Satsangi, Richard K Russell, 2008, Gastroenterology.

The contribution of OCTN1/2 variants within the IBD5 locus to disease susceptibility and severity in Crohn's disease.

H. Drummond, E. Nimmo, J. Satsangi, 2005, Gastroenterology.

Analysis of Germline GLI1 Variation Implicates Hedgehog Signalling in the Regulation of Intestinal Inflammatory Pathways

M. Tremelling, M. Parkes, H. Drummond, 2008, PLoS medicine.

Hepatobiliary cystadenoma with mesenchymal stroma may mimic biliary smooth muscle neoplasms

O. Garden, I. Arnott, J. Piris, 2001, Histopathology.

Autophagy gene ATG16L1 influences susceptibility and disease location but not childhood‐onset in Crohn's disease in Northern Europe

H. Drummond, J. Satsangi, G. Davies, 2008, Inflammatory bowel diseases.

Contribution of the NOD1/CARD4 insertion/deletion polymorphism +32656 to inflammatory bowel disease in Northern Europe#

H. Drummond, E. Nimmo, J. Satsangi, 2007, Inflammatory bowel diseases.

DLG5 variants do not influence susceptibility to inflammatory bowel disease in the Scottish population

H. Drummond, E. Nimmo, J. Satsangi, 2005, Gut.

Crohn’s disease

J. Satsangi, R. Kalla, I. Arnott, 2014, BMJ : British Medical Journal.

Lack of association between cervical dysplasia and IBD: A large case–control study

C. Lees, J. Satsangi, J. Critchley, 2009, Inflammatory bowel diseases.

Tolerability and safety of mercaptopurine in azathioprine‐intolerant patients with inflammatory bowel disease

C. Lees, J. Satsangi, B. Hansoti, 2007, Alimentary pharmacology & therapeutics.

A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta‐analysis

C. Lees, J. Satsangi, N. Kennedy, 2013, Alimentary pharmacology & therapeutics.

Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients

M. Parkes, C. Lees, J. Satsangi, 2014, Alimentary Pharmacology and Therapeutics.

Smoking Habit and Load Influence Age at Diagnosis and Disease Extent in Ulcerative Colitis

H. Drummond, J. Satsangi, I. Arnott, 2007, The American Journal of Gastroenterology.

Disease Location, Anti-Saccharomyces cerevisiae Antibody, and NOD2/CARD15 Genotype Influence the Progression of Disease Behavior in Crohn’s Disease

H. Drummond, E. Nimmo, J. Satsangi, 2004, Inflammatory bowel diseases.

Portal hypertension in the presence of minimal liver damage in Crohn's disease on long-term azathioprine: possible endothelial cell injury.

I. Arnott, S. Ghosh, Subrata Ghosh, 2000, European journal of gastroenterology & hepatology.

Clinical Utility And Diagnostic Accuracy of Faecal Calprotectin For IBD At First Presentation To Gastroenterology Services In Adults Aged 16–50 Years

C. Lees, J. Satsangi, N. Kennedy, 2014, Journal of Crohn's & colitis.

P459 Vedolizumab for the treatment of chronic pouchitis: the Edinburgh experience

C. Lees, I. Arnott, A. Shand, 2019, Journal of Crohn's and Colitis.

1043 The Efficacy of Corticosteroid Therapy: Analysis of 10-Year Inflammatory Bowel Disease Inception Cohort (1998-2007)

H. Drummond, J. Satsangi, I. Arnott, 2008 .

Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.

Teck Kiang Tan, J. Mansfield, Fraser Cummings, 2021, The lancet. Gastroenterology & hepatology.

Normalization of Fecal Calprotectin Within 12 Months of Diagnosis is Associated with Reduced Risk of Disease Progression in Patients with Crohn's Disease.

C. Lees, I. Arnott, S. Siakavellas, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

CAMBRIDGESHIRE AND PETERBOROUGH NHS FOUNDATION TRUST ELECTION TO THE COUNCIL OF GOVERNORS 2013

I. Arnott, Kirsty Trigg, 2013 .

Association Between Level of Fecal Calprotectin and Progression of Crohn's Disease

C. Lees, N. Kennedy, I. Arnott, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

The Management of Inflammatory Bowel Disease in Elderly: Current Evidence and Future Perspectives

G. Rogler, J. Halfvarson, I. Arnott, 2018, Inflammatory Intestinal Diseases.

Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease?

I. Arnott, S. Ghosh, D. Watts, 2002, Alimentary pharmacology & therapeutics.

PTU-002 Achieving biochemical remission in crohn’s disease with adalimumab therapy utilsing therapeutic drug monitoring

C. Lees, I. Arnott, C. Noble, 2018, IBD.

Technology Insight: the application of proteomics in gastrointestinal disease

J. Satsangi, A. Lennon, T. Hupp, 2007, Nature Clinical Practice Gastroenterology &Hepatology.

Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort

C. Lees, I. Arnott, C. Noble, 2023, United European gastroenterology journal.

SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement

M. Parkes, C. Lees, T. Ahmad, 2021, The Lancet Gastroenterology & Hepatology.

Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn's Disease Are Associated With Biologic Remission.

C. Lees, I. Arnott, G. Ho, 2018, Inflammatory bowel diseases.

Predicting outcomes in acute severe ulcerative colitis

J. Satsangi, N. Kennedy, R. Kalla, 2015, Expert review of gastroenterology & hepatology.

Fecal calprotectin: A selection tool for small bowel capsule endoscopy in suspected IBD with prior negative bi-directional endoscopy

Anastasios Koulaouzidis, I. Arnott, J. Plevris, 2011, Scandinavian journal of gastroenterology.

Association of trough vedolizumab levels with clinical, biological and endoscopic outcomes during maintenance therapy in inflammatory bowel disease

C. Lees, I. Arnott, R. Pattenden, 2019, Frontline Gastroenterology.

Barriers to transition care in inflammatory bowel disease: a survey of adult and paediatric gastroenterologists in the UK

R. Russell, S. McCartney, S. Sebastian, 2011, Gut.

Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts

C. Lees, I. Arnott, S. Siakavellas, 2021, Journal of Crohn's & colitis.

610 BOTH SINGLE AND MULTIPLE SWITCHING BETWEEN INFLIXIMAB BIOSIMILARS CAN BE SAFE AND EFFECTIVE IN INFLAMMATORY BOWEL DISEASE (IBD): REAL WORLD OUTCOMES FROM THE EDINBURGH IBD UNIT

C. Lees, I. Arnott, S. Siakavellas, 2021 .

PMO-48 Both single and multiple switching between infliximab biosimilars can be safe and effective in ibd

C. Lees, I. Arnott, L. Derikx, 2021, Posters.

564 Elevated Faecal Calprotectin Predicts Disease Progression in Crohn's Disease

Thomas J. Smith, H. Drummond, C. Lees, 2013 .

Endoscopic ultrasonography in the diagnosis and management of suspected upper gastrointestinal submucosal tumours

I. Arnott, J. Plevris, E. Shen, 2002, The British journal of surgery.

COVID-19: Colorectal cancer endoscopic surveillance in IBD

D. Gaya, I. Arnott, S. Din, 2021, The Lancet Gastroenterology & Hepatology.

Clinical and genetic factors predict severe disease: a novel composite severity index

J. Satsangi, C. Mowat, N. Lewin-Koh, 2011, Gut.

Sensitivity and inter-observer variability for capsule endoscopy image analysis in a cohort of novice readers.

Ian Arnott, Rome Jutabha, P. Enayati, 2006, World journal of gastroenterology.

Incidence of collagenous colitis in NHS Lothian: a population-based study

I. Arnott, K. Kirkwood, P. Fineron, 2021, Frontline Gastroenterology.

The Clinical Utility of Wireless Capsule Endoscopy

Simon K. Lo, S. Lo, I. Arnott, 2004, Digestive Diseases and Sciences.

Diverticular disease in Scotland: 2000–2010

P. Hodgkins, I. Arnott, R. Nicholls, 2015, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

P416 Real world data on the effectiveness and safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis: the Edinburgh experience.

C. Lees, J. Satsangi, I. Arnott, 2017, Journal of Crohn's & colitis.

Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16-50years

J. Satsangi, N. Kennedy, I. Arnott, 2014 .

Genome-Wide Methylation Profiling in 229 Patients With Crohn’s Disease Requiring Intestinal Resection: Epigenetic Analysis of the Trial of Prevention of Post-operative Crohn’s Disease (TOPPIC)

R. Prescott, C. Lees, J. Satsangi, 2023, Cellular and molecular gastroenterology and hepatology.

Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohn's disease.

C. Lees, I. Arnott, S. Siakavellas, 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Abnormal intestinal permeability predicts relapse in patients with inactive Crohn's disease

Subrata Ghosh, A. Ferguson, I. Arnott, 1998 .

OWE-27 Analysis of UC colectomy rates in pre- and post- biologic era South-East Scotland

C. Lees, M. Dunlop, I. Arnott, 2019, Colon and Anorectum.

PTU-122 A trial with mercaptopurine following azathioprine intolerance is a safe treatment strategy for the majority of patients with IBD

C. Lees, J. Satsangi, N. Kennedy, 2012, Gut.

The prevalence and transcriptional activity of the mucosal microbiota of ulcerative colitis patients

S. Heath, H. Drummond, C. Lees, 2018, Scientific Reports.

Toll-like receptor 4 gene in IBD : further evidence for genetic heterogeneity in Europe

J. Satsangi, E. Nimmo, I. Arnott, 2004 .

Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial

A. Forbes, S. Schreiber, C. Probert, 2003, Gut.